Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stribild Insulin Resistance Study in Healthy Volunteers
NCT02203461Phase 1Completed
- Sponsor
- Technical University of Munich
- Start
- Jul 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Technical University of Munich. Primary endpoint: Changes in insulin resistance at 14 days. Started Jul 2014; status: completed.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02203461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203461.